Brad Boeve

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4384639/publications.pdf

Version: 2024-02-01

489 papers	61,988 citations	1612 108 h-index	1311 230 g-index
508 all docs	508 docs citations	508 times ranked	39484 citing authors

#	Article	IF	Citations
1	Proposed research criteria for prodromal behavioural variant frontotemporal dementia. Brain, 2022, 145, 1079-1097.	3.7	30
2	Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases. Brain, 2022, 145, 27-44.	3.7	38
3	Rare PSAP Variants and Possible Interaction with GBA in REM Sleep Behavior Disorder. Journal of Parkinson's Disease, 2022, 12, 333-340.	1.5	3
4	The temporal onset of the core features in dementia with Lewy bodies. Alzheimer's and Dementia, 2022, 18, 591-601.	0.4	19
5	The contribution of behavioral features to caregiver burden in FTLD spectrum disorders. Alzheimer's and Dementia, 2022, 18, 1635-1649.	0.4	9
6	The National Institute on Aging Lateâ€Onset Alzheimer's Disease Family Based Study: A resource for genetic discovery. Alzheimer's and Dementia, 2022, 18, 1889-1897.	0.4	9
7	TDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration. NeuroImage: Clinical, 2022, 34, 102954.	1.4	3
8	Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration. Brain Communications, 2022, 4, fcac013.	1.5	15
9	TDP-43 represses cryptic exon inclusion in the FTDâ€“ALS gene UNC13A. Nature, 2022, 603, 124-130.	13.7	193
10	Phenotypic subtypes of progressive dysexecutive syndrome due to Alzheimerâ€™s disease: a series of clinical cases. Journal of Neurology, 2022, 269, 4110-4128.	1.8	7
11	A computational model of neurodegeneration in Alzheimerâ€™s disease. Nature Communications, 2022, 13, 1643.	5.8	32
12	Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations. Lancet Neurology, The, 2022, 21, 258-272.	4.9	63
13	Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies. Movement Disorders, 2022, 37, 1256-1264.	2.2	11
14	Poly (ADP-Ribose) and Î±â€“synuclein extracellular vesicles in patients with Parkinson disease: A possible biomarker of disease severity. PLoS ONE, 2022, 17, e0264446.	1.1	6
15	Shared brain transcriptomic signature in TDP-43 type A FTLD patients with or without GRN mutations. Brain, 2022, 145, 2472-2485.	3.7	6
16	Abnormal rapid eye movement sleep atonia control in chronic post-traumatic stress disorder. Sleep, 2022, 45, .	0.6	7
17	Objective sleep profile in LGI1/CASPR2 autoimmunity. Sleep, 2022, 45, .	0.6	11
18	Cognition and driving ability in isolated and symptomatic REM sleep behavior disorder. Sleep, 2022, 45, .	0.6	1

#	Article	IF	Citations
19	Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders. Cell Reports Medicine, 2022, 3, 100607.	3.3	21
20	Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations. Translational Neurodegeneration, 2022, 11, 24.	3.6	6
21	Deep learning-based brain age prediction in normal aging and dementia. Nature Aging, 2022, 2, 412-424.	5.3	52
22	Frequency and distribution of TAR DNA-binding protein 43 (TDP-43) pathology increase linearly with age in a large cohort of older adults with and without dementia. Acta Neuropathologica, 2022, 144, 159-160.	3.9	14
23	Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds. Journal of Alzheimer's Disease, 2022, 87, 1537-1547.	1.2	4
24	Sensitivity of the Social Behavior Observer Checklist to Early Symptoms of Patients With Frontotemporal Dementia. Neurology, 2022, , 10.1212/WNL.0000000000200582.	1.5	0
25	0268 Characterization of Neurodegenerative Disorder Subtypes Based on Non-REM Hypertonia and Sleep Spindle Duration. Sleep, 2022, 45, A121-A121.	0.6	0
26	0266 Sleep Spindle-Duration: A Potential Biomarker for Neurodegenerative Disorder Phenotyping. Sleep, 2022, 45, A120-A120.	0.6	0
27	0269 Non-REM sleep Hypertonia in Parkinsonian-Spectrum Disorders. Sleep, 2022, 45, A121-A122.	0.6	0
28	0267 The Influence of Antidepressants on Non-REM Hypertonia. Sleep, 2022, 45, A120-A121.	0.6	0
29	Behavioral Variant Frontotemporal Dementia. CONTINUUM Lifelong Learning in Neurology, 2022, 28, 702-725.	0.4	3
30	ASLPrep: a platform for processing of arterial spin labeled MRI and quantification of regional brain perfusion. Nature Methods, 2022, 19, 683-686.	9.0	13
31	Timeline of Rapid Eye Movement Sleep Behavior Disorder in Overt <scp>Alphaâ€Synucleinopathies</scp>. Annals of Neurology, 2021, 89, 293-303.	2.8	12
32	Comprehensive Analysis of Familial Parkinsonism Genes in Rapidâ€Eyeâ€Movement Sleep Behavior Disorder. Movement Disorders, 2021, 36, 235-240.	2.2	11
33	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. NeuroImage, 2021, 224, 117433.	2.1	63
34	Association of Initial Î²-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. JAMA Neurology, 2021, 78, 217.	4.5	27
35	Brain volumetric deficits in MAPT mutation carriers: a multisite study. Annals of Clinical and Translational Neurology, 2021, 8, 95-110.	1.7	21
36	Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder. Brain, 2021, 144, 278-287.	3.7	68

#	Article	IF	Citations
37	The value of multimodal imaging with 123I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia. Neurobiology of Aging, 2021, 99, 11-18.	1.5	11
38	Uniform data set language measures for bvFTD and PPA diagnosis and monitoring. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12148.	1.2	13
39	Î²-Amyloid PET and ¹²³ I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia. Neurology, 2021, 96, .	1.5	13
40	FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD. NeuroImage: Clinical, 2021, 31, 102754.	1.4	27
41	Dementia with Lewy bodies research consortia: A global perspective from the ISTAART Lewy Body Dementias Professional Interest Area working group. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12235.	1.2	6
42	Clinical and Neuroimaging Aspects of Familial Frontotemporal Lobar Degeneration Associated with MAPT and GRN Mutations. Advances in Experimental Medicine and Biology, 2021, 1281, 77-92.	0.8	3
43	APOE É4 Allele Testing and Risk of Alzheimer Disease. JAMA - Journal of the American Medical Association, 2021, 325, 484.	3.8	11
44	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	9.4	198
45	TAR DNA-Binding Protein 43 Is Associated with Rate of Memory, Functional and Global Cognitive Decline in the Decade Prior to Death. Journal of Alzheimer's Disease, 2021, 80, 683-693.	1.2	7
46	Specialist approaches to prognostic counseling in isolated REM sleep behavior disorder. Sleep Medicine, 2021, 79, 107-112.	0.8	19
47	Long-read targeted sequencing uncovers clinicopathological associations for C9orf72-linked diseases. Brain, 2021, 144, 1082-1088.	3.7	17
48	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. Neurology, 2021, 96, e2296-e2312.	1.5	52
49	Cerebral Amyloid Angiopathy Burden and Cerebral Microbleeds: Pathological Evidence for Distinct Phenotypes. Journal of Alzheimer's Disease, 2021, 81, 113-122.	1.2	8
50	Protocol for an observational cohort study identifying factors predicting accurately end of life in dementia with Lewy bodies and promoting quality end-of-life experiences: the PACE-DLB study. BMJ Open, 2021, 11, e047554.	0.8	2
51	MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease. Journal of Neuroimaging, 2021, 31, 1020-1027.	1.0	13
52	Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks. Brain, 2021, 144, 3212-3225.	3.7	26
53	Recognition memory and divergent cognitive profiles in prodromal genetic frontotemporal dementia. Cortex, 2021, 139, 99-115.	1.1	12
54	APOE Allele Testing and Alzheimer Diseaseâ€"Reply. JAMA - Journal of the American Medical Association, 2021, 325, 2211.	3.8	2

#	Article	IF	Citations
55	Lewy Body Dementia Associationâ€™s Industry Advisory Council: proceedings of the second annual meeting. Alzheimer's Research and Therapy, 2021, 13, 124.	3.0	1
56	Biomarkers of conversion to Î±-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder. Lancet Neurology, The, 2021, 20, 671-684.	4.9	116
57	Posterior cortical atrophy phenotypic heterogeneity revealed by decoding 18F-FDG-PET. Brain Communications, 2021, 3, fcab182.	1.5	12
58	Outcome Measures for Dementia With Lewy Body Clinical Trials. Alzheimer Disease and Associated Disorders, 2021, Publish Ahead of Print, .	0.6	9
59	Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid-Î² PET Signal. Neurology, 2021, 97, e1799-e1808.	1.5	10
60	Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic. Cell, 2021, 184, 4651-4668.e25.	13.5	97
61	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. NeuroImage, 2021, 238, 118259.	2.1	24
62	Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency. JAMA Network Open, 2021, 4, e2125584.	2.8	18
63	Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurology, The, 2021, 20, 739-752.	4.9	220
64	APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia. Science Translational Medicine, 2021, 13, eabc9375.	5.8	37
65	Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. Neurobiology of Aging, 2021, 105, 252-261.	1.5	18
66	Novel Associations of BST1 and LAMP3 With REM Sleep Behavior Disorder. Neurology, 2021, 96, e1402-e1412.	1.5	12
67	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. Frontiers in Neurology, 2021, 12, 805135.	1.1	12
68	Association between contact sports participation and chronic traumatic encephalopathy: a retrospective cohort study. Brain Pathology, 2020, 30, 63-74.	2.1	66
69	Use of the CDRÂ® plus NACC FTLD in mild FTLD: Data from the ARTFL/LEFFTDS consortium. Alzheimer's and Dementia, 2020, 16, 79-90.	0.4	48
70	The longitudinal evaluation of familial frontotemporal dementia subjects protocol: Framework and methodology. Alzheimer's and Dementia, 2020, 16, 22-36.	0.4	32
71	New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures. Alzheimer's and Dementia, 2020, 16, 131-143.	0.4	45
72	Active lifestyles moderate clinical outcomes in autosomal dominant frontotemporal degeneration. Alzheimer's and Dementia, 2020, 16, 91-105.	0.4	27

#	Article	IF	Citations
73	Linear vs volume measures of ventricle size. Neurology, 2020, 94, e549-e556.	1.5	19
74	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	4.9	175
75	Incidence of frontotemporal disorders in Olmsted County: A populationâ€based study. Alzheimer's and Dementia, 2020, 16, 482-490.	0.4	11
76	Tauâ€positron emission tomography correlates with neuropathology findings. Alzheimer's and Dementia, 2020, 16, 561-571.	0.4	113
77	REM sleep atonia loss distinguishes synucleinopathy in older adults with cognitive impairment. Neurology, 2020, 94, e15-e29.	1.5	25
78	Î²-Amyloid PET and neuropathology in dementia with Lewy bodies. Neurology, 2020, 94, e282-e291.	1.5	65
79	Î²-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. Neurology, 2020, 95, e3257-e3268.	1.5	62
80	The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation. Parkinsonism and Related Disorders, 2020, 79, 121-126.	1.1	11
81	Predicting future rates of tau accumulation on PET. Brain, 2020, 143, 3136-3150.	3.7	74
82	Quality of life and caregiver burden in familial frontotemporal lobar degeneration: Analyses of symptomatic and asymptomatic individuals within the LEFFTDS cohort. Alzheimer's and Dementia, 2020, 16, 1115-1124.	0.4	11
83	Association of ABI3 and PLCG2 missense variants with disease risk and neuropathology in Lewy body disease and progressive supranuclear palsy. Acta Neuropathologica Communications, 2020, 8, 172.	2.4	8
84	Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials. Alzheimer's Research and Therapy, 2020, 12, 137.	3.0	32
85	Case Report: Early-Onset Behavioral Variant Frontotemporal Dementia in Patient With Retrotransposed Full-Length Transcript of Matrin-3 Variant 5. Frontiers in Neurology, 2020, 11, 600468.	1.1	5
86	Studying the natural history of frontotemporal lobar degeneration (FTLD): The ARTFL LEFFTDS longitudinal FTLD (ALLFTD) protocol. Alzheimer's and Dementia, 2020, 16, e045482.	0.4	0
87	MAPT subhaplotypes in corticobasal degeneration: assessing associations with disease risk, severity of tau pathology, and clinical features. Acta Neuropathologica Communications, 2020, 8, 218.	2.4	8
88	Rates of Brain Atrophy Across Disease Stages in Familial Frontotemporal Dementia Associated With MAPT, GRN, and C9orf72 Pathogenic Variants. JAMA Network Open, 2020, 3, e2022847.	2.8	19
89	Protein contributions to brain atrophy acceleration in Alzheimerâ€™s disease and primary age-related tauopathy. Brain, 2020, 143, 3463-3476.	3.7	45
90	Progressive dysexecutive syndrome due to Alzheimerâ€™s disease: a description of 55 cases and comparison to other phenotypes. Brain Communications, 2020, 2, fcaa068.	1.5	81

#	Article	IF	Citations
91	Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy. Neurology, 2020, 95, e23-e34.	1.5	27
92	Longitudinal neuroimaging biomarkers differ across Alzheimerâ€™s disease phenotypes. Brain, 2020, 143, 2281-2294.	3.7	51
93	<scp>Alphaâ€Synuclein</scp> Oligomers and Neurofilament Light Chain in Spinal Fluid Differentiate Multiple System Atrophy from Lewy Body Synucleinopathies. Annals of Neurology, 2020, 88, 503-512.	2.8	78
94	Levodopa-induced dyskinesia in dementia with Lewy bodies and Parkinson disease with dementia. Neurology: Clinical Practice, 2020, 10, 156-161.	0.8	4
95	Subtypes of dementia with Lewy bodies are associated with Î±-synuclein and tau distribution. Neurology, 2020, 95, e155-e165.	1.5	47
96	Autonomic dysfunction and phenoconversion in idiopathic REM sleep behavior disorder. Clinical Autonomic Research, 2020, 30, 207-213.	1.4	23
97	Confirmation of ¹²³I-FP-CIT SPECT Quantification Methods in Dementia with Lewy Bodies and Other Neurodegenerative Disorders. Journal of Nuclear Medicine, 2020, 61, 1628-1635.	2.8	18
98	Witnessed apneas are associated with elevated tau-PET levels in cognitively unimpaired elderly. Neurology, 2020, 94, e1793-e1802.	1.5	28
99	Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. Brain, 2020, 143, 1632-1650.	3.7	158
100	Longitudinal structural and metabolic changes in frontotemporal dementia. Neurology, 2020, 95, e140-e154.	1.5	39
101	GBA variants in REM sleep behavior disorder. Neurology, 2020, 95, e1008-e1016.	1.5	45
102	0787 Autonomic Dysfunction and Phenoconversion in Idiopathic/Isolated REM Sleep Behavior Disorder. Sleep, 2020, 43, A300-A300.	0.6	0
103	Longitudinal clinical, neuropsychological, and neuroimaging characterization of a kindred with a 12-octapeptide repeat insertion in PRNP: the next generation. Neurocase, 2020, 26, 211-219.	0.2	4
104	18F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies. Brain Communications, 2020, 2, fcaa040.	1.5	17
105	Diagnostic value of plasma phosphorylated tau181 in Alzheimerâ€™s disease and frontotemporal lobar degeneration. Nature Medicine, 2020, 26, 387-397.	15.2	471
106	Trajectory of lobar atrophy in asymptomatic and symptomatic GRN mutation carriers: a longitudinal MRI study. Neurobiology of Aging, 2020, 88, 42-50.	1.5	14
107	Fineâ€Mapping of SNCA in Rapid Eye Movement Sleep Behavior Disorder and Overt Synucleinopathies. Annals of Neurology, 2020, 87, 584-598.	2.8	39
108	Tracking disease progression in familial and sporadic frontotemporal lobar degeneration: Recent findings from ARTFL and LEFFTDS. Alzheimer's and Dementia, 2020, 16, 71-78.	0.4	33

#	Article	IF	Citations
109	Utility of the global CDR^{Â®} plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium. Alzheimer's and Dementia, 2020, 16, 106-117.	0.4	81
110	Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimerâ€™s Disease Neuropathological Changes. Journal of Alzheimer's Disease, 2020, 73, 1511-1523.	1.2	14
111	TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional/diffuse Lewy body disease. Journal of Neurology, 2020, 267, 1444-1453.	1.8	4
112	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. Annals of Clinical and Translational Neurology, 2020, 7, 707-721.	1.7	17
113	Association between transactive response DNA-binding protein ofÂ43 kDa type and cognitive resilience to Alzheimerâ€™s disease: aÂcase-control study. Neurobiology of Aging, 2020, 92, 92-97.	1.5	13
114	Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology, 2020, 94, 743-755.	1.5	365
115	Pickâ€™s disease: clinicopathologic characterization of 21 cases. Journal of Neurology, 2020, 267, 2697-2704.	1.8	17
116	SMPD1 variants do not have a major role in rapid eye movement sleep behavior disorder. Neurobiology of Aging, 2020, 93, 142.e5-142.e7.	1.5	4
117	Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. Journal of Clinical Investigation, 2020, 130, 6080-6092.	3.9	117
118	Revised Self-Monitoring Scale. Neurology, 2020, 94, e2384-e2395.	1.5	23
119	Longitudinal anatomic, functional, and molecular characterization of Pick disease phenotypes. Neurology, 2020, 95, e3190-e3202.	1.5	13
120	Rates of lobar atrophy in asymptomatic MAPT mutation carriers. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 338-346.	1.8	22
121	Comparison of the Short Test of Mental Status and the Montreal Cognitive Assessment Across the Cognitive Spectrum. Mayo Clinic Proceedings, 2019, 94, 1516-1523.	1.4	35
122	Submentalis Rapid Eye Movement Sleep Muscle Activity: A Potential Biomarker for Synucleinopathy. Annals of Neurology, 2019, 86, 969-974.	2.8	14
123	Extensive transcriptomic study emphasizes importance of vesicular transport in C9orf72 expansion carriers. Acta Neuropathologica Communications, 2019, 7, 150.	2.4	40
124	REM sleep muscle activity in idiopathic REM sleep behavior disorder predicts phenoconversion. Neurology, 2019, 93, e1171-e1179.	1.5	45
125	A Comprehensive Resource for Induced Pluripotent Stem Cells from Patients with Primary Tauopathies. Stem Cell Reports, 2019, 13, 939-955.	2.3	62
126	The bivariate distribution of amyloid-Î² and tau: relationship with established neurocognitive clinical syndromes. Brain, 2019, 142, 3230-3242.	3.7	129

#	Article	IF	Citations
127	Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. Brain, 2019, 142, 3621-3635.	3.7	37
128	Transient Epileptic Amnesia: A Treatable Cause of Spells Associated With Persistent Cognitive Symptoms. Frontiers in Neurology, 2019, 10, 939.	1.1	17
129	Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers. Neurobiology of Aging, 2019, 83, 54-62.	1.5	14
130	Normative and isolated rapid eye movement sleep without atonia in adults without REM sleep behavior disorder. Sleep, 2019, 42, .	0.6	25
131	Longitudinal multimodal imaging and clinical endpoints for frontotemporal dementia clinical trials. Brain, 2019, 142, 443-459.	3.7	65
132	Physician and patient determinants of prognostic counseling in idiopathic REM sleep-behavior disorder. Sleep Medicine, 2019, 62, 80-85.	0.8	18
133	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimerâ€™s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathologica, 2019, 138, 237-250.	3.9	87
134	Brain MR Spectroscopy Changes Precede Frontotemporal Lobar Degeneration Phenoconversion in Mapt Mutation Carriers. Journal of Neuroimaging, 2019, 29, 624-629.	1.0	9
135	Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease. Alzheimer's and Dementia, 2019, 15, 927-939.	0.4	48
136	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. Neurology, 2019, 93, e29-e39.	1.5	62
137	Neuroprotection in idiopathic REM sleep behavior disorder: a role for exercise?. Sleep, 2019, 42, .	0.6	9
138	Lewy Body Dementia Associationâ€™s Research Centers of Excellence Program: Inaugural Meeting Proceedings. Alzheimer's Research and Therapy, 2019, 11, 23.	3.0	9
139	Association of MAPT Subhaplotypes With Risk of Progressive Supranuclear Palsy and Severity of Tau Pathology. JAMA Neurology, 2019, 76, 710.	4.5	39
140	Thalamo-cortical network hyperconnectivity in preclinical progranulin mutation carriers. NeuroImage: Clinical, 2019, 22, 101751.	1.4	30
141	CSF1R mutation presenting as dementia with Lewy bodies. Neurocase, 2019, 25, 17-20.	0.2	9
142	Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain, 2019, 142, 744-759.	3.7	636
143	Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy. Movement Disorders, 2019, 34, 1144-1153.	2.2	98
144	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathologica, 2019, 137, 879-899.	3.9	90

#	Article	IF	Citations
145	Excessive Daytime Sleepiness in Major Dementia Syndromes. American Journal of Alzheimer's Disease and Other Dementias, 2019, 34, 261-264.	0.9	14
146	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates AÎ², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962
147	Entorhinal cortex tau, amyloid-Î², cortical thickness and memory performance in non-demented subjects. Brain, 2019, 142, 1148-1160.	3.7	68
148	Association of Longitudinal Î²-Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia. JAMA Network Open, 2019, 2, e1916439.	2.8	22
149	Multimodal imaging in familial FTLD: phenoconversion and planning for the future. Brain, 2019, 142, 8-11.	3.7	18
150	¹⁸Fâ€AVâ€1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy. Movement Disorders, 2019, 34, 344-352.	2.2	26
151	The influence of Î²-amyloid on [¹⁸ F]AV-1451 in semantic variant of primary progressive aphasia. Neurology, 2019, 92, e710-e722.	1.5	10
152	REM Sleep Behavior Disorder Associated with Dementia with Lewy Bodies. , 2019, , 67-76.		2
153	Frontal lobe ¹ H MR spectroscopy in asymptomatic and symptomatic MAPT mutation carriers. Neurology, 2019, 93, e758-e765.	1.5	18
154	Joint associations of Î²-amyloidosis and cortical thickness with cognition. Neurobiology of Aging, 2018, 65, 121-131.	1.5	27
155	Elevated medial temporal lobe and pervasive brain tauâ€PET signal in normal participants. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 210-216.	1.2	19
156	[¹⁸F]AVâ€1451 tauâ€PET and primary progressive aphasia. Annals of Neurology, 2018, 83, 599-611.	2.8	73
157	When Do Î±-Synucleinopathies Start? An Epidemiological Timeline. JAMA Neurology, 2018, 75, 503.	4.5	69
158	Tau-negative amnestic dementia masquerading as Alzheimer disease dementia. Neurology, 2018, 90, e940-e946.	1.5	24
159	In vivo ¹⁸ F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms. Neurology, 2018, 90, e947-e954.	1.5	60
160	Clinicopathological and ¹²³Iâ€<scp>FP</scp>â€<scp>CIT SPECT</scp> correlations in patients with dementia. Annals of Clinical and Translational Neurology, 2018, 5, 376-381.	1.7	11
161	Progranulin. Neurology, 2018, 90, 118-125.	1.5	20
162	[¹⁸F]AVâ€1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. Annals of Neurology, 2018, 83, 248-257.	2.8	67

#	Article	IF	Citations
163	Widespread brain tau and its association with ageing, Braak stage and Alzheimerâ€™s dementia. Brain, 2018, 141, 271-287.	3.7	218
164	Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Annals of Neurology, 2018, 83, 166-177.	2.8	479
165	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	4.9	97
166	Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1005-1014.	0.4	80
167	Association of Excessive Daytime Sleepiness With Longitudinal Î²-Amyloid Accumulation in Elderly Persons Without Dementia. JAMA Neurology, 2018, 75, 672.	4.5	150
168	FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis. Brain, 2018, 141, 1201-1217.	3.7	67
169	Association Between Microinfarcts and Blood Pressure Trajectories. JAMA Neurology, 2018, 75, 212.	4.5	15
170	Depressive and anxiety symptoms and cortical amyloid deposition among cognitively normal elderly persons: the Mayo Clinic Study of Aging. International Psychogeriatrics, 2018, 30, 245-251.	0.6	52
171	The limbic and neocortical contribution of Î±â€synuclein, tau, and amyloid Î² to disease duration in dementia with Lewy bodies. Alzheimer's and Dementia, 2018, 14, 330-339.	0.4	69
172	Pittsburgh compound B (PiB) PET imaging of meningioma and other intracranial tumors. Journal of Neuro-Oncology, 2018, 136, 373-378.	1.4	9
173	Amyloid- and tau-PET imaging in a familial prion kindred. Neurology: Genetics, 2018, 4, e290.	0.9	4
174	O5â€03â€04: THE LEWY BODY DEMENTIA ASSOCIATION RESEARCH CENTERS OF EXCELLENCE PROGRAM: TOWARD OPTIMIZING CLINICAL CARE AND CLINICAL TRIAL INFRASTRUCTURE. Alzheimer's and Dementia, 2018, 14, P1646.	0.4	0
175	Electroencephalogram findings in patients with posterior cortical atrophy. Neurologia I Neurochirurgia Polska, 2018, 52, 690-694.	0.6	1
176	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain, 2018, 141, 2895-2907.	3.7	39
177	Association of Apolipoprotein E Îµ4 With Transactive Response DNA-Binding Protein 43. JAMA Neurology, 2018, 75, 1347.	4.5	60
178	Tau Mutations as a Novel Risk Factor for Cancerâ€”Letter. Cancer Research, 2018, 78, 6523-6524.	0.4	2
179	ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans. Molecular Neurodegeneration, 2018, 13, 53.	4.4	75
180	REM sleep behaviour disorder. Nature Reviews Disease Primers, 2018, 4, 19.	18.1	290

#	Article	IF	Citations
181	Full sequencing and haplotype analysis of MAPT in Parkinson's disease and rapid eye movement sleep behavior disorder. Movement Disorders, 2018, 33, 1016-1020.	2.2	31
182	Regional cortical perfusion on arterial spin labeling MRI in dementia with Lewy bodies: Associations with clinical severity, glucose metabolism and tau PET. NeuroImage: Clinical, 2018, 19, 939-947.	1.4	31
183	Predictors of neural-specific autoantibodies and immunotherapy response in patients with cognitive dysfunction. Journal of Neuroimmunology, 2018, 323, 62-72.	1.1	68
184	Multimodal imaging in RBD â€" present and future. Nature Reviews Neurology, 2018, 14, 574-576.	4.9	1
185	APOE Îµ4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. Neurology, 2018, 91, e1182-e1195.	1.5	122
186	Orthostatic Hypotension as a Prodromal Marker of Î±-Synucleinopathiesâ€"Reply. JAMA Neurology, 2018, 75, 1155.	4.5	1
187	Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype. Acta Neuropathologica, 2018, 136, 389-404.	3.9	59
188	Diagnostic REM sleep muscle activity thresholds in patients with idiopathic REM sleep behavior disorder with and without obstructive sleep apnea. Sleep Medicine, 2017, 33, 23-29.	0.8	59
189	Duration and Pathologic Correlates of Lewy Body Disease. JAMA Neurology, 2017, 74, 310.	4.5	48
190	A robust biomarker of largeâ€scale network failure in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 152-161.	1.2	29
191	Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). Acta Neuropathologica, 2017, 133, 705-715.	3.9	125
192	Frontotemporal dementia with the V337M MAPT mutation. Neurology, 2017, 88, 758-766.	1.5	76
193	Polygenic risk scores in familial Alzheimer disease. Neurology, 2017, 88, 1180-1186.	1.5	59
194	Consensus classification of posterior cortical atrophy. Alzheimer's and Dementia, 2017, 13, 870-884.	0.4	423
195	Lewy Body Dementias. Focus (American Psychiatric Publishing), 2017, 15, 85-100.	0.4	2
196	Survival and Causes of Death Among People With Clinically Diagnosed Synucleinopathies With Parkinsonism. JAMA Neurology, 2017, 74, 839.	4.5	68
197	Efficacy, Safety, and Tolerability of Armodafinil Therapy for Hypersomnia Associated with Dementia with Lewy Bodies: A Pilot Study. Dementia and Geriatric Cognitive Disorders, 2017, 43, 269-280.	0.7	39
198	<scp>REM</scp><scp>S</scp>leep <scp>B</scp>ehavior <scp>D</scp>isorder in <scp>P</scp>arkinson's <scp>D</scp>isease and <scp>O</scp>ther <scp>S</scp>ynucleinopathies. Movement Disorders, 2017, 32, 645-658.	2.2	139

#	Article	IF	Citations
199	In-depth clinico-pathological examination of RNA foci in a large cohort of C9ORF72 expansion carriers. Acta Neuropathologica, 2017, 134, 255-269.	3.9	76
200	Phenoconversion from probable rapid eye movement sleep behavior disorder to mild cognitive impairment to dementia in a populationâ€based sample. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 127-130.	1.2	6
201	Diagnosis and management of dementia with Lewy bodies. Neurology, 2017, 89, 88-100.	1.5	2,805
202	White-matter integrity on DTI and the pathologic staging of Alzheimer's disease. Neurobiology of Aging, 2017, 56, 172-179.	1.5	158
203	MR Elastography Demonstrates Unique Regional Brain Stiffness Patterns in Dementias. American Journal of Roentgenology, 2017, 209, 403-408.	1.0	68
204	High School Football and Late-Life Risk of Neurodegenerative Syndromes, 1956-1970. Mayo Clinic Proceedings, 2017, 92, 66-71.	1.4	81
205	Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum. Cortex, 2017, 97, 143-159.	1.1	162
206	[P2â€“317]: PHENOCONVERSION FROM ASYMPTOMATIC TO MINIMALLY SYMPTOMATIC FTLD: PRELIMINARY DATA IN THE LEFFTDS COHORT. Alzheimer's and Dementia, 2017, 13, P739.	0.4	0
207	Rapid Eye Movement Sleep Behavior Disorder. , 2017, , 1069-1086.		0
208	Uptake of AV-1451 in meningiomas. Annals of Nuclear Medicine, 2017, 31, 736-743.	1.2	7
209	Clinicopathologic discrepancies in a populationâ€based incidence study of parkinsonism in olmsted county: 1991â€2010. Movement Disorders, 2017, 32, 1439-1446.	2.2	19
210	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
211	REM Sleep Behavior Disorder: Diagnosis, Clinical Implications, and Future Directions. Mayo Clinic Proceedings, 2017, 92, 1723-1736.	1.4	143
212	Abnormal expression of homeobox genes and transthyretin in C9ORF72 expansion carriers. Neurology: Genetics, 2017, 3, e161.	0.9	12
213	AVâ€1451 tau and Î²â€amyloid positron emission tomography imaging in dementia with Lewy bodies. Annals of Neurology, 2017, 81, 58-67.	2.8	152
214	Excessive daytime sleepiness and fatigue may indicate accelerated brain aging in cognitively normal late middle-aged and older adults. Sleep Medicine, 2017, 32, 236-243.	0.8	79
215	FTDPâ€17 with Pick bodyâ€like inclusions associated with a novel tau mutation, p.E372G. Brain Pathology, 2017, 27, 612-626.	2.1	11
216	An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 257-266.	0.4	41

#	Article	IF	Citations
217	[P1â€“334]: CHARACTERIZATION OF THE CLINICAL AND NEUROIMAGING FEATURES OF PATIENTS WITH DEMENTIA WITH LEWY BODIES ASSOCIATED WITH VARIANTS IN GLUCOCEREBROSIDASE (GBA). Alzheimer's and Dementia, 2017, 13, P384.	0.4	0
218	¹ H-MRS metabolites and rate of Î²-amyloid accumulation on serial PET in clinically normal adults. Neurology, 2017, 89, 1391-1399.	1.5	18
219	Novel GRN mutation presenting as an aphasic dementia and evolving into corticobasal syndrome. Neurology: Genetics, 2017, 3, e201.	0.9	2
220	Rapid Eye Movement Sleep Parasomnias. , 2017, , 993-1001.e6.		3
221	Letter on â€œNatural history of pure autonomic failure: A United States prospective cohortâ€• Annals of Neurology, 2017, 81, 910-910.	2.8	2
222	Alzheimer Disease and Other Dementias. , 2017, , 935-943.e6.		3
223	A 76 Year-Old Woman with Sleep and Waking Stridor, Sleep Talking, Orthostatic Hypotension, and Imbalance. Journal of Clinical Sleep Medicine, 2016, 12, 143-145.	1.4	0
224	Globular Glial Tauopathy Presenting as Semantic Variant Primary Progressive Aphasia. JAMA Neurology, 2016, 73, 123.	4.5	21
225	MAPT haplotype diversity in multiple system atrophy. Parkinsonism and Related Disorders, 2016, 30, 40-45.	1.1	23
226	P3â€255: PET TAU Imaging with AVâ€1451 in Microtubuleâ€Associated Protein TAU (MAPT) Mutation Carriers Relative to Alzheimerâ€™S Disease Dementia and Controls. Alzheimer's and Dementia, 2016, 12, P927.	0.4	0
227	ICâ€P â€180: PET TAU Imaging With AVâ€1451 in Microtubule Associated Protein TAU (MAPT) Mutation Carriers Relative to Alzheimerâ€™s Disease Dementia and Controls. Alzheimer's and Dementia, 2016, 12, P131.	0.4	0
228	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 862-871.	0.4	93
229	RAB39B gene mutations are not a common cause of Parkinson's disease or dementia with Lewy bodies. Neurobiology of Aging, 2016, 45, 107-108.	1.5	21
230	Magnetic resonance elastography of frontotemporal dementia. Journal of Magnetic Resonance Imaging, 2016, 43, 474-478.	1.9	56
231	Network-driven plasma proteomics expose molecular changes in the Alzheimerâ€™s brain. Molecular Neurodegeneration, 2016, 11, 31.	4.4	34
232	Autoimmune dementia and encephalopathy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 247-267.	1.0	16
233	Sleep Disturbances in Frontotemporal Dementia. Current Neurology and Neuroscience Reports, 2016, 16, 85.	2.0	57
234	Arguing against the proposed definition changes of PD. Movement Disorders, 2016, 31, 1619-1622.	2.2	55

#	Article	IF	Citations
235	TYROBP genetic variants in early-onset Alzheimer's disease. Neurobiology of Aging, 2016, 48, 222.e9-222.e15.	1.5	69
236	Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant transcripts. Science, 2016, 353, 708-712.	6.0	116
237	TREM2 p.R47H substitution is not associated with dementia with Lewy bodies. Neurology: Genetics, 2016, 2, e85.	0.9	16
238	The Role of Cardiovascular Risk Factors and Stroke in Familial Alzheimer Disease. JAMA Neurology, 2016, 73, 1231.	4.5	49
239	An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathologica Communications, 2016, 4, 58.	2.4	388
240	Comparison of Gait Parameters forÂPredicting Cognitive Decline: TheÂMayoÂClinic Study of Aging. Journal of Alzheimer's Disease, 2016, 55, 559-567.	1.2	79
241	LRRK2 variation and dementia with Lewy bodies. Parkinsonism and Related Disorders, 2016, 31, 98-103.	1.1	30
242	Amyloid-Î² deposition and regional grey matter atrophy rates in dementia with Lewy bodies. Brain, 2016, 139, 2740-2750.	3.7	68
243	Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia. Neurology, 2016, 87, 691-698.	1.5	22
244	Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum. Neurobiology of Aging, 2016, 46, 32-42.	1.5	20
245	Hippocampal volumes predict risk of dementia with Lewy bodies in mild cognitive impairment. Neurology, 2016, 87, 2317-2323.	1.5	44
246	CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia. Nature Communications, 2016, 7, 11253.	5.8	174
247	MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies. Alzheimer's and Dementia, 2016, 12, 1297-1304.	0.4	32
248	Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry. Movement Disorders, 2016, 31, 989-994.	2.2	32
249	Cascading network failure across the Alzheimerâ€™s disease spectrum. Brain, 2016, 139, 547-562.	3.7	401
250	Magnetic resonance elastography of frontotemporal dementia. Journal of Magnetic Resonance Imaging, 2016, 43, spcone.	1.9	2
251	Neuromelanin-sensitive imaging in patients with idiopathic rapid eye movement sleep behaviour disorder. Brain, 2016, 139, 1005-1007.	3.7	6
252	A Young Man With Progressive Language Difficulty and Early-Onset Dementia. JAMA Neurology, 2016, 73, 595.	4.5	0

#	Article	IF	Citations
253	Plasma sphingolipid changes with autopsyâ€confirmed Lewy body or Alzheimer's pathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 3, 43-50.	1.2	44
254	Evaluating pathogenic dementia variants in posterior cortical atrophy. Neurobiology of Aging, 2016, 37, 38-44.	1.5	23
255	Association of traumatic brain injury with subsequent neurological and psychiatric disease: a meta-analysis. Journal of Neurosurgery, 2016, 124, 511-526.	0.9	280
256	Sleep issues in dementia. , 2016, , 446-469.		1
257	Ramelteon for Idiopathic REM Sleep Behavior Disorder: Implications for Pathophysiology and Future Treatment Trials. Journal of Clinical Sleep Medicine, 2016, 12, 643-645.	1.4	8
258	Genetic variants associated with susceptibility to psychosis inÂlate-onset Alzheimerâ€™s disease families. Neurobiology of Aging, 2015, 36, 3116.e9-3116.e16.	1.5	14
259	Antidepressants Increase REM Sleep Muscle Tone in Patients with and without REM Sleep Behavior Disorder. Sleep, 2015, 38, 907-17.	0.6	86
260	Diabetes is Associated with Worse ExecutiveÂFunction in Both Eastern andÂWestern Populations: Shanghai Aging Study andÂMayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2015, 47, 167-176.	1.2	23
261	Rarity of the Alzheimer Diseaseâ€“ProtectiveAPPA673T Variant in the United States. JAMA Neurology, 2015, 72, 209.	4.5	41
262	Mitochondrial targeting sequence variants of the CHCHD2 gene are a risk for Lewy body disorders. Neurology, 2015, 85, 2016-2025.	1.5	51
263	Neuroimaging-evident lesional pathology associated with REM sleep behavior disorder. Sleep Medicine, 2015, 16, 1502-1510.	0.8	45
264	Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e161.	3.1	163
265	Chronic traumatic encephalopathy pathology in a neurodegenerative disorders brain bank. Acta Neuropathologica, 2015, 130, 877-889.	3.9	235
266	O5-03-01: Longitudinal evaluation of familial frontotemporal dementia subjects (LEFFTDS): Subject characteristics, aims, and methodology. , 2015, 11, P318-P319.		0
267	Melatonin therapy for REM sleep behavior disorder: a critical review of evidence. Sleep Medicine, 2015, 16, 19-26.	0.8	149
268	Invited review: Frontotemporal dementia caused by microtubuleâ€associated protein tau gene (<scp>MAPT</scp>) mutations: a chameleon for neuropathology and neuroimaging. Neuropathology and Applied Neurobiology, 2015, 41, 24-46.	1.8	360
269	Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nature Communications, 2015, 6, 7247.	5.8	170
270	Frequency and topography of cerebral microbleeds in dementia with Lewy bodies compared to Alzheimer's disease. Parkinsonism and Related Disorders, 2015, 21, 1101-1104.	1.1	27

#	Article	IF	Citations
271	Risk and protective factors for cognitive impairment in persons aged 85 years and older. Neurology, 2015, 84, 1854-1861.	1.5	61
272	White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging. Neurobiology of Aging, 2015, 36, 2010-2017.	1.5	35
273	Lewy body dementias. Lancet, The, 2015, 386, 1683-1697.	6.3	422
274	Role of Î²-Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment. JAMA Neurology, 2015, 72, 1475.	4.5	23
275	Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72. Acta Neuropathologica, 2015, 130, 863-876.	3.9	104
276	Spectrum of cognition short of dementia. Neurology, 2015, 85, 1712-1721.	1.5	67
277	Cerebellar c9RAN proteins associate with clinical and neuropathological characteristics of C9ORF72 repeat expansion carriers. Acta Neuropathologica, 2015, 130, 559-573.	3.9	89
278	Improving clinical cognitive testing. Neurology, 2015, 85, 910-918.	1.5	36
279	Role for the microtubule-associated protein tau variant p.A152T in risk of Î±-synucleinopathies. Neurology, 2015, 85, 1680-1686.	1.5	31
280	Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. Neurobiology of Aging, 2015, 36, 452-461.	1.5	113
281	MRS in Mild Cognitive Impairment: Early Differentiation of Dementia with Lewy Bodies and Alzheimer's Disease. Journal of Neuroimaging, 2015, 25, 269-274.	1.0	24
282	Sleep, Cognitive Dysfunction, and Dementia. , 2015, , 285-300.		1
283	Abnormal daytime sleepiness in dementia with Lewy bodies compared to Alzheimerâ€™s disease using the Multiple Sleep Latency Test. Alzheimer's Research and Therapy, 2014, 6, 76.	3.0	45
284	Antemortem MRI findings associated with microinfarcts at autopsy. Neurology, 2014, 82, 1951-1958.	1.5	45
285	Association of hypometabolism and amyloid levels in aging, normal subjects. Neurology, 2014, 82, 1959-1967.	1.5	73
286	Long-Term Exercise Training for an Individual With Mixed Corticobasal Degeneration and Progressive Supranuclear Palsy Features: 10-Year Case Report Follow-up. Physical Therapy, 2014, 94, 289-296.	1.1	26
287	The GGGGCC Repeat Expansion inC9ORF72in a Case with Discordant Clinical and FDG-PET Findings: PET Trumps Syndrome. Neurocase, 2014, 20, 110-120.	0.2	15
288	Greatest rapid eye movement sleep atonia loss in men and older age. Annals of Clinical and Translational Neurology, 2014, 1, 733-738.	1.7	22

#	Article	IF	Citations
289	Early Alzheimer's Disease Neuropathology Detected by Proton MR Spectroscopy. Journal of Neuroscience, 2014, 34, 16247-16255.	1.7	117
290	Age-Specific Incidence Rates for Dementia and Alzheimer Disease in NIA-LOAD/NCRAD and EFIGA Families. JAMA Neurology, 2014, 71, 315.	4.5	48
291	Genetic modifiers in carriers of repeat expansions in the C9ORF72 gene. Molecular Neurodegeneration, 2014, 9, 38.	4.4	63
292	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1394.	4.5	166
293	Hypothyroidism and Risk of Mild Cognitive Impairment in Elderly Persons. JAMA Neurology, 2014, 71, 201.	4.5	48
294	Chiari 1 Malformation Presenting as Central Sleep Apnea during Pregnancy: A Case Report, Treatment Considerations, and Review of the Literature. Frontiers in Neurology, 2014, 5, 195.	1.1	6
295	Dementia with Lewy bodies. Neurology, 2014, 83, 801-809.	1.5	143
296	Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies. Neurobiology of Aging, 2014, 35, 1483-1490.	1.5	29
297	Association of diabetes with amnestic and nonamnestic mild cognitiveÂimpairment. Alzheimer's and Dementia, 2014, 10, 18-26.	0.4	141
298	Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. Neurobiology of Aging, 2014, 35, 2421.e13-2421.e17.	1.5	74
299	A population-based study of the association between bullous pemphigoid and neurologic disorders. Journal of the American Academy of Dermatology, 2014, 71, 1191-1197.	0.6	81
300	A familial form of parkinsonism, dementia, and motor neuron disease: A longitudinal study. Parkinsonism and Related Disorders, 2014, 20, 1129-1134.	1.1	6
301	Lesional REM sleep behavior disorder localizes to the dorsomedial pons. Neurology, 2014, 83, 1871-1873.	1.5	40
302	Progranulin protein levels are differently regulated in plasma and CSF. Neurology, 2014, 82, 1871-1878.	1.5	70
303	Discovery of a Biomarker and Lead Small Molecules to Target r(GGGGCC)-Associated Defects in c9FTD/ALS. Neuron, 2014, 83, 1043-1050.	3.8	289
304	Factors associated with injury in REM sleep behavior disorder. Sleep Medicine, 2014, 15, 1332-1338.	0.8	78
305	TDP-43 is a key player in the clinical features associated with Alzheimerâ€™s disease. Acta Neuropathologica, 2014, 127, 811-824.	3.9	336
306	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	4.9	302

#	Article	IF	Citations
307	18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. Neurobiology of Aging, 2014, 35, 2096-2106.	1.5	108
308	Diagnostic Thresholds for Quantitative REM Sleep Phasic Burst Duration, Phasic and Tonic Muscle Activity, and REM Atonia Index in REM Sleep Behavior Disorder with and without Comorbid Obstructive Sleep Apnea. Sleep, 2014, 37, 1649-1662.	0.6	105
309	IC-P-062: DATSCAN FINDINGS IN PATIENTS WITH REM SLEEP BEHAVIOR DISORDER AND/OR COGNITIVE IMPAIRMENT. , 2014, 10, P35-P35.		0
310	PL-04-02: COMPLEXITIES OF LEWY BODY DISEASE. , 2014, 10, P248-P248.		0
311	Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Medicine, 2013, 14, 744-748.	0.8	688
312	Is rapid eye movement sleep behavior disorder in Parkinson disease a specific disease subtype?. Sleep Medicine, 2013, 14, 931-933.	0.8	10
313	Mild cognitive impairment in rapid eye movement sleep behavior disorder: a predictor of dementia?. Sleep Medicine, 2013, 14, 1041-1042.	0.8	3
314	Treatment of Dementia With Lewy Bodies. Current Treatment Options in Neurology, 2013, 15, 738-764.	0.7	30
315	Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies. Neurology, 2013, 81, 2032-2038.	1.5	191
316	MRI and pathology of REM sleep behavior disorder in dementia with Lewy bodies. Neurology, 2013, 81, 1681-1689.	1.5	58
317	Treatment outcomes in REM sleep behavior disorder. Sleep Medicine, 2013, 14, 237-242.	0.8	202
318	Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease. Lancet Neurology, The, 2013, 12, 469-482.	4.9	164
319	Mild cognitive impairment due to Alzheimer disease in the community. Annals of Neurology, 2013, 74, 199-208.	2.8	215
320	C9ORF72 repeat expansions in cases with previously identified pathogenic mutations. Neurology, 2013, 81, 1332-1341.	1.5	84
321	Clinical and electrophysiologic variability in amyotrophic lateral sclerosis within a kindred harboring theC9ORF72repeat expansion. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 132-137.	1.1	7
322	Polysomnographic Findings in Dementia With Lewy Bodies. Neurologist, 2013, 19, 1-6.	0.4	75
323	Incidence of Dementia With Lewy Bodies and Parkinson Disease Dementia. JAMA Neurology, 2013, 70, 1396.	4.5	250
324	Restless legs syndrome and daytime sleepiness are prominent in myotonic dystrophy type 2. Neurology, 2013, 81, 157-164.	1.5	36

#	Article	IF	Citations
325	Practice Effects and Longitudinal Cognitive Change in Normal Aging vs. Incident Mild Cognitive Impairment and Dementia in The Mayo Clinic Study of Aging. Clinical Neuropsychologist, 2013, 27, 1247-1264.	1.5	124
326	Clinical Phenomenology and Mortality in Charles Bonnet Syndrome. Journal of Geriatric Psychiatry and Neurology, 2013, 26, 3-9.	1.2	14
327	C9orf72 Hexanucleotide Repeat Expansions in Clinical Alzheimer Disease. JAMA Neurology, 2013, 70, 736.	4.5	92
328	Subtle gait changes in patients with REM sleep behavior disorder. Movement Disorders, 2013, 28, 1847-1853.	2.2	53
329	Validation of the Mayo Sleep Questionnaire to Screen for REM Sleep Behavior Disorder in a Community-Based Sample. Journal of Clinical Sleep Medicine, 2013, 09, 475-480.	1.4	128
330	Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain, 2012, 135, 794-806.	3.7	355
331	Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain, 2012, 135, 765-783.	3.7	322
332	Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology, 2012, 79, 1570-1577.	1.5	146
333	Shapes of the Trajectories of 5 Major Biomarkers of Alzheimer Disease. Archives of Neurology, 2012, 69, 856-67.	4.9	99
334	Characterization of a Family With c9FTD/ALS Associated With the GGGGCC Repeat Expansion in C9ORF72. Archives of Neurology, 2012, 69, 1164-9.	4.9	17
335	Mild cognitive impairment associated with underlying Alzheimer's disease versus Lewy body disease. Parkinsonism and Related Disorders, 2012, 18, S41-S44.	1.1	51
336	Progressive supranuclear palsy. Parkinsonism and Related Disorders, 2012, 18, S192-S194.	1.1	33
337	ApoE and Quality of Life in Nonagenarians. Journal of the American Medical Directors Association, 2012, 13, 704-707.	1.2	2
338	Cognitive and behavioral features of c9FTD/ALS. Alzheimer's Research and Therapy, 2012, 4, 29.	3.0	20
339	Steroid-responsive encephalopathy subsequently associated with Alzheimer's disease pathology: A case series. Neurocase, 2012, 18, 1-12.	0.2	9
340	Ante mortem amyloid imaging and Î²-amyloid pathology in a case with dementia with Lewy bodies. Neurobiology of Aging, 2012, 33, 878-885.	1.5	69
341	The chromosome 9 ALS and FTD locus is probably derived from a single founder. Neurobiology of Aging, 2012, 33, 209.e3-209.e8.	1.5	115
342	Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiology of Aging, 2012, 33, 2091-2105.	1.5	162

#	Article	IF	Citations
343	Length of normal alleles of C9ORF72 GGGGCC repeat do not influence disease phenotype. Neurobiology of Aging, 2012, 33, 2950.e5-2950.e7.	1.5	83
344	Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. Lancet Neurology, The, 2012, 11, 868-877.	4.9	355
345	Limb immobilization and corticobasal syndrome. Parkinsonism and Related Disorders, 2012, 18, 1097-1099.	1.1	2
346	Sleep in Parkinsonâ€™s Disease and Dementia with Lewy Bodies. Advances in Biological Psychiatry, 2012, , 61-70.	0.2	4
347	Non-Stationarity in the â€œResting Brainâ€™sâ€•Modular Architecture. PLoS ONE, 2012, 7, e39731.	1.1	382
348	REM Sleep Behavior Disorder and REM Sleep Without Atonia as an Early Manifestation of Degenerative Neurological Disease. Current Neurology and Neuroscience Reports, 2012, 12, 182-192.	2.0	106
349	Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. Brain, 2012, 135, 2470-2477.	3.7	64
350	Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies. Neurology, 2012, 79, 553-560.	1.5	91
351	An operational approach to National Institute on Agingâ€“Alzheimer's Association criteria for preclinical Alzheimer disease. Annals of Neurology, 2012, 71, 765-775.	2.8	520
352	Rapid eye movement sleep behavior disorder and subtypes in autopsyâ€confirmed dementia with Lewy bodies. Movement Disorders, 2012, 27, 72-78.	2.2	99
353	Probable rapid eye movement sleep behavior disorder increases risk for mild cognitive impairment and Parkinson disease: A populationâ€based study. Annals of Neurology, 2012, 71, 49-56.	2.8	179
354	Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain, 2011, 134, 2456-2477.	3.7	3,913
355	Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND. NeuroImage, 2011, 55, 522-531.	2.1	90
356	Neuropsychological assessment of patients with dementing illness. Nature Reviews Neurology, 2011, 7, 677-687.	4.9	55
357	Probable RBD is increased in Parkinsonâ€™s disease but not in essential tremor or restless legs syndrome. Parkinsonism and Related Disorders, 2011, 17, 456-458.	1.1	73
358	Incidental Lewy body disease: Do some cases represent a preclinical stage of dementia with Lewy bodies?. Neurobiology of Aging, 2011, 32, 857-863.	1.5	136
359	Temporoparietal atrophy: A marker of AD pathology independent of clinical diagnosis. Neurobiology of Aging, 2011, 32, 1531-1541.	1.5	105
360	Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. Sleep Medicine, 2011, 12, 445-453.	0.8	236

#	Article	IF	Citations
361	Neuropsychological Characterization of Evolving Cognitive Decline in Idiopathic REM Sleep Behavior Disorder Is Important, But Not Easy. Sleep, 2011, 34, 561-562.	0.6	6
362	What is the quality of life in the oldest old?. International Psychogeriatrics, 2011, 23, 1003-1010.	0.6	30
363	Clinical Characterization of a Kindred With a Novel 12-Octapeptide Repeat Insertion in the Prion Protein Gene. Archives of Neurology, 2011, 68, 1165.	4.9	25
364	Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. Neuron, 2011, 72, 245-256.	3.8	4,176
365	Imaging Signatures of Molecular Pathology in Behavioral Variant Frontotemporal Dementia. Journal of Molecular Neuroscience, 2011, 45, 372-8.	1.1	61
366	The Multiple Phenotypes of Corticobasal Syndrome and Corticobasal Degeneration: Implications for Further Study. Journal of Molecular Neuroscience, 2011, 45, 350-353.	1.1	78
367	Anatomy of disturbed sleep in pallidoâ€pontoâ€nigral degeneration. Annals of Neurology, 2011, 69, 1014-1025.	2.8	10
368	The strong presence of REM sleep behavior disorder in PD: Clinical and research implications. Neurology, 2011, 77, 1030-1032.	1.5	32
369	Sleep Disturbance in Dementia with Lewy Bodies and Alzheimerâ€™s Disease: A Multicenter Analysis. Dementia and Geriatric Cognitive Disorders, 2011, 31, 239-246.	0.7	75
370	Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome. Brain, 2011, 134, 3264-3275.	3.7	119
371	Sleep disorders in neurodegenerative diseases other than Parkinson's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2011, 99, 1011-1050.	1.0	5
372	Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 196-203.	0.9	170
373	Alzheimer's Disease and Other Dementias. , 2011, , 1038-1047.		5
374	Alzheimer Diseaseâ€“like Phenotype Associated With the c.154delA Mutation in Progranulin. Archives of Neurology, 2010, 67, 171-7.	4.9	59
375	Predicting the future in idiopathic rapid-eye movement sleep behaviour disorder. Lancet Neurology, The, 2010, 9, 1040-1042.	4.9	17
376	Anatomical differences between CBSâ€corticobasal degeneration and CBSâ€Alzheimer's disease. Movement Disorders, 2010, 25, 1246-1252.	2.2	71
377	Frequency and Correlates of Caregiverâ€Reported Sleep Disturbances in a Sample of Persons with Early Dementia. Journal of the American Geriatrics Society, 2010, 58, 480-486.	1.3	112
378	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nature Genetics, 2010, 42, 234-239.	9.4	479

#	Article	IF	Citations
379	REM sleep behavior disorder. Annals of the New York Academy of Sciences, 2010, 1184, 15-54.	1.8	531
380	Progress on Progranulin. Archives of Neurology, 2010, 67, 145-7.	4.9	3
381	Positron Emission Tomographyâ€“Computed Tomography in Paraneoplastic Neurologic Disorders. Archives of Neurology, 2010, 67, 322.	4.9	131
382	Mild cognitive impairment associated with limbic and neocortical lewy body disease: a clinicopathological study. Brain, 2010, 133, 540-556.	3.7	195
383	Autoimmune Dementia: Clinical Course and Predictors of Immunotherapy Response. Mayo Clinic Proceedings, 2010, 85, 881-897.	1.4	158
384	Symmetric corticobasal degeneration (S-CBD). Parkinsonism and Related Disorders, 2010, 16, 208-214.	1.1	56
385	Neuropsychiatric features of dementia. , 2009, , 85-100.		4
386	Mild cognitive impairment. , 2009, , 172-187.		1
387	MRI Correlates of Protein Deposition and Disease Severity in Postmortem Frontotemporal Lobar Degeneration. Neurodegenerative Diseases, 2009, 6, 106-117.	0.8	47
388	Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain, 2009, 132, 583-591.	3.7	344
389	Comparison of ¹⁸F-FDG and PiB PET in Cognitive Impairment. Journal of Nuclear Medicine, 2009, 50, 878-886.	2.8	183
390	Mild Cognitive Impairment. Archives of Neurology, 2009, 66, 1447-55.	4.9	1,160
391	Alzheimer's disease and corticobasal degeneration presenting as corticobasal syndrome. Movement Disorders, 2009, 24, 1375-1379.	2.2	105
392	Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study. Brain, 2009, 132, 2932-2946.	3.7	277
393	Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain, 2009, 132, 1355-1365.	3.7	975
394	Prominent phenotypic variability associated with mutations in Progranulin. Neurobiology of Aging, 2009, 30, 739-751.	1.5	166
395	Comparison of Risk Factor Profiles in Incidental Lewy Body Disease and Parkinson Disease. Archives of Neurology, 2009, 66, 1114-9.	4.9	34
396	Age and apoE associations with complex pathologic features in Alzheimer's disease. Journal of the Neurological Sciences, 2008, 273, 34-39.	0.3	30

#	Article	IF	Citations
397	Update on the Diagnosis and Management of Sleep Disturbances in Dementia. Sleep Medicine Clinics, 2008, 3, 347-360.	1.2	22
398	Voxel-based morphometry in autopsy proven PSP and CBD. Neurobiology of Aging, 2008, 29, 280-289.	1.5	221
399	Current and future management of the corticobasal syndrome and corticobasal degeneration. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 533-548.	1.0	17
400	Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. NeuroImage, 2008, 42, 559-567.	2.1	152
401	Occurrence and clinical correlates of REM sleep behaviour disorder in patients with Parkinson's disease over time. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 387-391.	0.9	211
402	Validation of the Neuropathologic Criteria of the Third Consortium for Dementia With Lewy Bodies for Prospectively Diagnosed Cases. Journal of Neuropathology and Experimental Neurology, 2008, 67, 649-656.	0.9	137
403	Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain, 2008, 131, 2957-2968.	3.7	354
404	Young-Onset Dementia. Archives of Neurology, 2008, 65, 1502.	4.9	113
405	Novel Mutations in TARDBP (TDP-43) in Patients with Familial Amyotrophic Lateral Sclerosis. PLoS Genetics, 2008, 4, e1000193.	1.5	393
406	Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Human Molecular Genetics, 2008, 17, 3631-3642.	1.4	271
407	Refining Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17. Archives of Neurology, 2008, 65, 460.	4.9	162
408	11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain, 2008, 131, 665-680.	3.7	819
409	The Mayo Clinic Study of Aging: Design and Sampling, Participation, Baseline Measures and Sample Characteristics. Neuroepidemiology, 2008, 30, 58-69.	1.1	623
410	Very Early Semantic Dementia With Progressive Temporal Lobe Atrophy. Archives of Neurology, 2008, 65, 1659-63.	4.9	26
411	Frontotemporal Dementia Mimicking Dementia With Lewy Bodies. Cognitive and Behavioral Neurology, 2008, 21, 157-163.	0.5	50
412	Long-Term Locomotor Training for Gait and Balance in a Patient With Mixed Progressive Supranuclear Palsy and Corticobasal Degeneration. Physical Therapy, 2007, 87, 1078-1087.	1.1	34
413	An 81-year-old man with imbalance and memory impairment. Neurology, 2007, 68, 1147-1152.	1.5	4
414	Distinctive MRI findings in pallidopontonigral degeneration (PPND). Neurology, 2007, 68, 620-621.	1.5	13

#	Article	IF	Citations
415	Voxel-Based Morphometry in Frontotemporal Lobar Degeneration With Ubiquitin-Positive Inclusions With and Without Progranulin Mutations. Archives of Neurology, 2007, 64, 371.	4.9	82
416	Links Between Frontotemporal Lobar Degeneration, Corticobasal Degeneration, Progressive Supranuclear Palsy, and Amyotrophic Lateral Sclerosis. Alzheimer Disease and Associated Disorders, 2007, 21, S31-S38.	0.6	65
417	Clinical Features and Survival of 3R and 4R Tauopathies Presenting as Behavioral Variant Frontotemporal Dementia. Alzheimer Disease and Associated Disorders, 2007, 21, S39-S43.	0.6	23
418	Frontotemporal Dementia Treatment: Current Symptomatic Therapies and Implications of Recent Genetic, Biochemical, and Neuroimaging Studies. Alzheimer Disease and Associated Disorders, 2007, 21, S79-S87.	0.6	74
419	SLEEP AND NEURODEGENERATIVE DISORDERS. CONTINUUM Lifelong Learning in Neurology, 2007, 13, 201-224.	0.4	1
420	Neuropathologic Features of Frontotemporal Lobar Degeneration With Ubiquitin-Positive Inclusions With Progranulin Gene (PGRN) Mutations. Journal of Neuropathology and Experimental Neurology, 2007, 66, 142-151.	0.9	184
421	Autoimmune Encephalopathies. Neurologist, 2007, 13, 140-147.	0.4	150
422	Clinical-pathologic study of biomarkers in FTDP-17 (PPND family with N279K tau mutation). Parkinsonism and Related Disorders, 2007, 13, 230-239.	1.1	47
423	Imaging correlates of posterior cortical atrophy. Neurobiology of Aging, 2007, 28, 1051-1061.	1.5	176
424	Dementia with Lewy Bodies. Neurologic Clinics, 2007, 25, 741-760.	0.8	59
425	Implicit Learning of Sequential Regularities and Spatial Contexts in Corticobasal Syndrome. Neurocase, 2007, 13, 133-143.	0.2	16
426	Parkinson-Related Dementias. Neurologic Clinics, 2007, 25, 761-781.	0.8	36
427	The Degenerative Dementias. , 2007, , 699-733.		4
428	Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477Câ†'T (Arg493X) mutation: an international initiative. Lancet Neurology, The, 2007, 6, 857-868.	4.9	199
429	The Treatment of Parasomnias with Hypnosis: a 5-Year Follow-Up Study. Journal of Clinical Sleep Medicine, 2007, 03, 369-373.	1.4	77
430	Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain, 2006, 129, 1385-1398.	3.7	624
431	Neuropsychological Differentiation of Dementia with Lewy Bodies from Normal Aging and Alzheimer's Disease. Clinical Neuropsychologist, 2006, 20, 623-636.	1.5	170
432	A Preliminary Fluorodeoxyglucose Positron Emission Tomography Study in Healthy Adults Reporting Dream-Enactment Behavior. Sleep, 2006, 29, 927-933.	0.6	51

#	Article	IF	Citations
433	Absence of Rapid Eye Movement Sleep Behavior Disorder in 11 Members of the Pallidopontonigral Degeneration Kindred. Archives of Neurology, 2006, 63, 268.	4.9	27
434	Clinically Undetected Motor Neuron Disease in Pathologically Proven Frontotemporal Lobar Degeneration With Motor Neuron Disease. Archives of Neurology, 2006, 63, 506.	4.9	66
435	Atypical Progressive Supranuclear Palsy With Corticospinal Tract Degeneration. Journal of Neuropathology and Experimental Neurology, 2006, 65, 396-405.	0.9	129
436	Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature, 2006, 442, 916-919.	13.7	1,816
437	Rates of cerebral atrophy in autopsy-confirmed progressive supranuclear palsy. Annals of Neurology, 2006, 59, 200-203.	2.8	30
438	Frontotemporal dementia and parkinsonism associated with the IVS1+1G->A mutation in progranulin: a clinicopathologic study. Brain, 2006, 129, 3103-3114.	3.7	105
439	Neuropathologic Outcome of Mild Cognitive Impairment Following Progression to Clinical Dementia. Archives of Neurology, 2006, 63, 674.	4.9	377
440	Mutations in progranulin explain atypical phenotypes with variants in MAPT. Brain, 2006, 129, 3124-3126.	3.7	91
441	Rates of cerebral atrophy differ in different degenerative pathologies. Brain, 2006, 130, 1148-1158.	3.7	146
442	Depression, Apolipoprotein E Genotype, and the Incidence of Mild Cognitive Impairment. Archives of Neurology, 2006, 63, 435.	4.9	206
443	REM sleep behavior disorder: A possible early marker for synucleinopathies. Neurology, 2006, 66, 796-797.	1.5	68
444	Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Human Molecular Genetics, 2006, 15, 2988-3001.	1.4	529
445	Steroid-Responsive Encephalopathy Associated With Autoimmune Thyroiditis. Archives of Neurology, 2006, 63, 197.	4.9	470
446	REM sleep behavior disorder initiated by acute brainstem multiple sclerosis. Neurology, 2006, 66, 1277-1279.	1.5	102
447	A Review of the Non-Alzheimer Dementias. Journal of Clinical Psychiatry, 2006, 67, 1985-2001.	1.1	8
448	Clinical, diagnostic, genetic and management issues in dementia with Lewy bodies. Clinical Science, 2005, 109, 343-354.	1.8	15
449	Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium. Neurology, 2005, 65, 1863-1872.	1.5	4,604
450	Antemortem diagnosis of frontotemporal lobar degeneration. Annals of Neurology, 2005, 57, 480-488.	2.8	181

#	Article	IF	Citations
451	MRI correlates of alien leg-like phenomenon in corticobasal degeneration. Movement Disorders, 2005, 20, 870-873.	2.2	21
452	Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome. Movement Disorders, 2005, 20, 982-988.	2.2	111
453	Corticobasal Degeneration. , 2005, , 309-334.		12
454	REM Sleep Behavior Disorder and REM-Related Parasomnias. , 2005, , 435-441.		0
455	Longitudinal characterization of two siblings with frontotemporal dementia and parkinsonism linked to chromosome 17 associated with the S305N tau mutation. Brain, 2005, 128, 752-772.	3.7	55
456	Alzheimer's Disease and Other Dementias. , 2005, , 853-862.		4
457	Evidence for cholinesterase-inhibitor therapy for dementia associated with Parkinson's disease. Lancet Neurology, The, 2005, 4, 137-8.	4.9	3
458	DEMENTIA WITH LEWY BODIES. , 2004, , 911-926.		0
459	Involvement of medullary regions controlling sympathetic output in Lewy body disease. Brain, 2004, 128, 338-344.	3.7	70
460	REM Sleep Behavior Disorder in Parkinsonâ€™s Disease and Dementia with Lewy Bodies. Journal of Geriatric Psychiatry and Neurology, 2004, 17, 146-157.	1.2	229
461	DEMENTIA WITH LEWY BODIES. CONTINUUM Lifelong Learning in Neurology, 2004, 10, 81-112.	0.4	3
462	Correlation Between Antemortem Magnetic Resonance Imaging Findings and Pathologically Confirmed Corticobasal Degeneration. Archives of Neurology, 2004, 61, 1881-4.	4.9	67
463	Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Annals of Neurology, 2003, 54, S15-S19.	2.8	496
464	Essentials of the Proper Diagnoses of Mild Cognitive Impairment, Dementia, and Major Subtypes of Dementia. Mayo Clinic Proceedings, 2003, 78, 1290-1308.	1.4	187
465	EEG findings in steroid-responsive encephalopathy associated with autoimmune thyroiditis. Clinical Neurophysiology, 2003, 114, 32-37.	0.7	130
466	Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Medicine, 2003, 4, 281-284.	0.8	364
467	Progressive Nonfluent Aphasia and Subsequent Aphasic Dementia Associated with Atypical Progressive Supranuclear Palsy Pathology. European Neurology, 2003, 49, 72-78.	0.6	76
468	Mild cognitive impairment in the oldest old. Neurology, 2003, 60, 477-480.	1.5	70

#	Article	IF	Citations
469	Comparison of the Short Test of Mental Status and the Mini-Mental State Examination in Mild Cognitive Impairment. Archives of Neurology, 2003, 60, 1777.	4.9	158
470	Parkinson Disease Neuropathology. Archives of Neurology, 2002, 59, 102.	4.9	366
471	Dementia with Lewy bodies may present as dementia and REM sleep behavior disorder without parkinsonism or hallucinations. Journal of the International Neuropsychological Society, 2002, 8, 907-914.	1.2	124
472	A Presenilin 1 Mutation Associated with Familial Frontotemporal Dementia Inhibits Î³-Secretase Cleavage of APP and Notch. Neurobiology of Disease, 2002, 9, 269-273.	2.1	92
473	Current management of sleep disturbances in dementia. Current Neurology and Neuroscience Reports, 2002, 2, 169-177.	2.0	42
474	Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Movement Disorders, 2001, 16, 622-630.	2.2	587
475	A kinematic study of progressive apraxia with and without dementia. Movement Disorders, 1999, 14, 276-287.	2.2	20
476	2-30-01 Clinicopathologic heterogeneity in clinically- and/or pathologically-diagnosed cortical-basal ganglionic degeneration. Journal of the Neurological Sciences, 1997, 150, S109-S110.	0.3	4
477	Lewy body variant of alzheimer's disease (AD) identified by postmortem ubiquitin staining in a previously reported case of AD associated with REM sleep behavior disorder. Biological Psychiatry, 1997, 42, 527-528.	0.7	71
478	Persistent cauda equina syndrome following bilateral aortoiliac dissection as a complication of cardiac angiography. , 1997, 40, 377-379.		1
479	Dementia with Lewy bodies. , 0, , 7-26.		2
480	Early clinical features of the parkinsonian-related dementias. , 0, , 197-212.		2
481	Dementia treatment. , 0, , 213-253.		2
482	Early clinical features of the parkinsonian-related dementias. , 0, , 245-277.		1
483	The Lewy body dementias. , 0, , 278-300.		0
484	Neuropsychiatry of dementia. , 0, , 9-18.		0
485	Genetic approaches to neurodegenerative disease. , 0, , 57-76.		0
486	The non-fluent/agrammatic variant of primary progressive aphasia. , 0, , 164-177.		0

#	Article	IF	Citations
487	Cognitive disorders of the very old. , 0, , 425-434.		0
488	REM Sleep Behavior Disorder in Parkinson's Disease, Dementia with Lewy Bodies, and Multiple System Atrophy. , 0, , 383-398.		7
489	Sleepiness in Cognitively Unimpaired Older Adults Is Associated With CSF Biomarkers of Inflammation and Axonal Integrity. Frontiers in Aging Neuroscience, 0, 14, .	1.7	6